Clinical Trial

CPX-351 Plus Enasidenib for Relapsed AML

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 28, 2023 (before its estimated September 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2019-01-30; most recent amendment 2024-04-25.
Status change: Active, Not Recruiting → Terminated 2024-04-25
Status change: Suspended → Active, Not Recruiting 2023-09-26
Status change: Recruiting → Suspended 2021-10-06
Status change: Not Yet Recruiting → Recruiting 2019-04-19
Trial Details
NCT Number NCT03825796
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Jazz Pharmaceuticals
Conditions Recurrent Acute Myeloid Leukemia
Enrollment 2 participants
Start Date 2019-04-12
Primary Completion 2024-09-01 (estimated)
Study Completion 2024-09-01 (estimated)
Updated on ClinicalTrials.gov 2023-09-28